Rabbit anti-HIV-1 monoclonal antibodies raised by immunization can mimic the antigen-binding modes of antibodies derived from HIV-1-infected humans

Journal of Virology

Volumn 87, Issue 18, 2013, Pages 10221-10231

  Pan, Ruimin ^a   Sampson, Jared M ^a   Chen, Yuxin ^b   Vaine, Michael ^b   Wang, Shixia ^b   Lu, Shan ^b   Kong, Xiang Peng ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT;

ALLOTYPE; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; BETA SHEET; BINDING AFFINITY; BINDING SITE; CRYSTAL STRUCTURE; DISULFIDE BOND; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; CRYSTALLOGRAPHY, X-RAY; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; RABBITS;

EID: 84883261870     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00843-13     Document Type: Article

References (62)

1. Mage RG, Lanning D, Knight KL. 2006. B cell and antibody repertoire development in rabbits: the requirement of gut-associated lymphoid tissues. Dev. Comp. Immunol. 30:137-153.
2. Li WH, Gouy M, Sharp PM, O'HUigin C, Yang YW. 1990. Molecular phylogeny of Rodentia, Lagomorpha, Primates, Artiodactyla, and Carnivora and molecular clocks. Proc. Natl. Acad. Sci. U. S. A. 87:6703-6707.
3. Graur D, Duret L, Gouy M. 1996. Phylogenetic position of the order Lagomorpha (rabbits, hares and allies). Nature 379:333-335.
4. Novacek MJ. 1996. Taxonomy. Where do rabbits and kin fit in? Nature 379:299-300.
5. Popkov M, Mage RG, Alexander CB, Thundivalappil S, Barbas CF, III, Rader C. 2003. Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J. Mol. Biol. 325:325-335.
6. Ros F, Puels J, Reichenberger N, van Schooten W, Buelow R, Platzer J. 2004. Sequence analysis of 0.5Mbof the rabbit germline immunoglobulin heavy chain locus. Gene 330:49-59.
7. Ros F, Reichenberger N, Dragicevic T, van Schooten WC, Buelow R, Platzer J. 2005. Sequence analysis of 0.4 megabases of the rabbit germline immunoglobulin kappa1 light chain locus. Anim. Genet. 36:51-57.
8. Kwong PD, Mascola JR. 2012. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37:412-425.
9. Knight KL, Becker RS. 1990. Molecular basis of the allelic inheritance of rabbit immunoglobulin VH allotypes: implications for the generation of antibody diversity. Cell 60:963-970.
10. Sehgal D, Johnson G, Wu TT, Mage RG. 1999. Generation of the primary antibody repertoire in rabbits: expression of a diverse set of Igk-V genes may compensate for limited combinatorial diversity at the heavy chain locus. Immunogenetics 50:31-42.
11. Kabat EA, Wu TT, Perry HM, Gottesman KS. 1991. Sequences of proteins of immunological interest, 5th ed. National Institutes of Health, Bethesda, MD.
12. McCartney-Francis N, Skurla RM, Jr, Mage RG, Bernstein KE. 1984. Kappa-chain allotypes and isotypes in the rabbit: cDNA sequences of clones encoding b9 suggest an evolutionary pathway and possible role of the interdomain disulfide bond in quantitative allotype expression. Proc. Natl. Acad. Sci. U. S. A. 81:1794-1798.
13. Steiner LA. 1985. Immunoglobulin disulfide bridges: theme and variations. Biosci. Rep. 5:973-989.
14. McKeating JA, Gow J, Goudsmit J, Pearl LH, Mulder C, Weiss RA. 1989. Characterization of HIV-1 neutralization escape mutants. AIDS 3:777-784.
15. Ivanoff LA, Dubay JW, Morris JF, Roberts SJ, Gutshall L, Sternberg EJ, Hunter E, Matthews TJ, Petteway SR, Jr. 1992. V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. Virology 187:423-432.
16. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711.
17. Resch W, Hoffman N, Swanstrom R. 2001. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 288:51-62.
18. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD. 2005. Structure of a V3-containing HIV-1 gp120 core. Science 310:1025-1028.
19. Jiang X, Burke V, Totrov M, Williams C, Cardozo T, Gorny MK, Zolla-Pazner S, Kong XP. 2010. Conserved structural elements in the V3 crown of HIV-1 gp120. Nat. Struct. Mol. Biol. 17:955-961.
20. White-Scharf ME, Potts BJ, Smith LM, Sokolowski KA, Rusche JR, Silver S. 1993. Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization. Virology 192: 197-206.
21. Gorny M, Zolla-Pazner S. 2003. Human monoclonal antibodies that neutralize HIV-1, p 37-51. In Korber B, Brander C, Haynes BF, Koup RA, Moore JP, Walker B, Watkins DI (ed), HIV immunology and HIV/SIV vaccine databases 2003. Los Alamos National Laboratory, Los Alamos, NM.
22. Gorny MK, Wang XH, Williams C, Volsky B, Revesz K, Witover B, Burda S, Urbanski M, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S, Nadas A. 2009. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Mol. Immunol. 46:917-926.
23. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, Phogat A, Chakrabarti B, Li Y, Connors M, Pereyra F, Walker BD, Wardemann H, Ho D, Wyatt RT, Mascola JR, Ravetch JV, Nussenzweig MC. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIVinfected individuals. Nature 458:636-640.
24. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D, Jarrossay D, Balla-Jhagjhoorsingh S, Willems B, Zekveld MJ, Dreja H, O'Sullivan E, Pade C, Orkin C, Jeffs SA, Montefiori DC, Davis D, Weissenhorn W, McKnight A, Heeney JL, Sallusto F, Sattentau QJ, Weiss RA, Lanzavecchia A. 2010. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5:e8805. doi:10.1371/journal.pone.0008805.
25. Laman JD, Schellekens MM, Lewis GK, Moore JP, Matthews TJ, Langedijk JP, Meloen RH, Boersma WJ, Claassen E. 1993. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody. AIDS Res. Hum. Retroviruses 9:605-612.
26. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470.
27. Rini JM, Stanfield RL, Stura EA, Salinas PA, Profy AT, Wilson IA. 1993. Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. Proc. Natl. Acad. Sci. U. S. A. 90:6325-6329.
28. Ghiara JB, Stura EA, Stanfield RL, Profy AT, Wilson IA. 1994. Crystal structure of the principal neutralization site of HIV-1. Science 264:82-85.
29. Stanfield R, Cabezas E, Satterthwait A, Stura E, Profy A, Wilson I. 1999. Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing Fabs. Structure 7:131-142.
30. Sharon M, Kessler N, Levy R, Zolla-Pazner S, Gorlach M, Anglister J. 2003. Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure 11:225-236.
31. Stanfield RL, Ghiara JB, Ollmann Saphire E, Profy AT, Wilson IA. 2003. Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop. Virology 315:159-173.
32. Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA. 2004. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure 12:193-204.
33. Rosen O, Chill J, Sharon M, Kessler N, Mester B, Zolla-Pazner S, Anglister J. 2005. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization. Biochemistry 44:7250-7258.
34. Rosen O, Sharon M, Quadt-Akabayov SR, Anglister J. 2006. Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion. Proc. Natl. Acad. Sci. U. S. A. 103:13950-13955.
35. Stanfield RL, Gorny MK, Zolla-Pazner S, Wilson IA. 2006. Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J. Virol. 80:6093-6105.
36. Bell CH, Pantophlet R, Schiefner A, Cavacini LA, Stanfield RL, Burton DR, Wilson IA. 2008. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J. Mol. Biol. 375:969-978.
37. Dhillon AK, Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA. 2008. Structure determination of an anti-HIV-1 Fab 447-52Dpeptide complex from an epitaxially twinned data set. Acta Crystallogr. D Biol. Crystallogr. 64:792-802.
38. Burke V, Williams C, Sukumaran M, Kim S, Li H, WangX-H, Gorny MK, Zolla-Pazner S, Kong X-P. 2009. Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens. Structure 17:1538-1546.
39. Gorny MK, Sampson J, Li H, Jiang X, Totrov M, Wang XH, Williams C, O'Neal T, Volsky B, Li L, Cardozo T, Nyambi P, Zolla-Pazner S, Kong XP. 2011. Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure. PLoS One 6:e27780. doi:10.1371/journal.pone.0027780.
40. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097-1103.
41. Vaine M, Wang S, Hackett A, Arthos J, Lu S. 2010. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 28: 2999-3007.
42. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode, p 307-326. In Carter CW, Sweet R (ed), Macromolecular crystallography, part A, vol 276. Academic Press, Inc., New York, NY.
43. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AG, McCoy A, McNicholas SJ, Murshudov GN, Pannu NS, Potterton EA, Powell HR, Read RJ, Vagin A, Wilson KS. 2011. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67:235-242.
44. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC. 2002. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 58:1948-1954.
45. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132.
46. Abagyan RA, Totrov M, Kuznetsov D. 1994. ICM-a new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation. J. Comput. Chem. 15: 488-506.
47. DeLano WL. 2002. The PyMOL user's manual. DeLano Scientific, Palo Alto, CA.
48. Abhinandan KR, Martin AC. 2008. Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains. Mol. Immunol. 45:3832-3839.
49. Ratner L, Fisher A, Jagodzinski LL, Mitsuya H, Liou RS, Gallo RC, Wong-Staal F. 1987. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res. Hum. Retroviruses 3:57-69.
50. Arai H, Glabe C, Luecke H. 2012. Crystal structure of a conformationdependent rabbit IgG Fab specific for amyloid prefibrillar oligomers. Biochim. Biophys. Acta 1820:1908-1914.
51. Spurrier B, Sampson JM, Totrov M, Li H, O'Neal T, Williams C, Robinson J, Gorny MK, Zolla-Pazner S, Kong XP. 2011. Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120. Structure 19:691-699.
52. LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P, et al. 1990. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 249:932-935. (Erratum, 251:811, 1991.)
53. Vranken WF, Fant F, Budesinsky M, Borremans FA. 2001. Conformational model for the consensus V3 loop of the envelope protein gp120 of HIV-1 in a 20% trifluoroethanol/water solution. Eur. J. Biochem. 268: 2620-2628.
54. Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, Hussan SS, Stanfield RL, Robinson J, Sodroski J, Wilson IA, Wyatt R, Bewley CA, Kwong PD. 2007. Structures of the CCR5 N terminus and of a tyrosinesulfated antibody with HIV-1 gp120 and CD4. Science 317:1930-1934.
55. Tugarinov V, Zvi A, Levy R, Hayek Y, Matsushita S, Anglister J. 2000. NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding. Structure 8:385-395.
56. Walker LM, Sok D, Nishimura Y, Donau O, Sadjadpour R, Gautam R, Shingai M, Pejchal R, Ramos A, Simek MD, Geng Y, Wilson IA, Poignard P, Martin MA, Burton DR. 2011. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc. Natl. Acad. Sci. U. S. A. 108:20125-20129.
57. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams MR, Lambson BE, Ranchobe N, Ping L, Ngandu N, Abdool Karim Q, Abdool Karim SS, Swanstrom RI, Seaman MS, Williamson C, Morris L. 2012. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 18:1688-1692.
58. Raaphorst FM, Raman CS, Nall BT, Teale JM. 1997. Molecular mechanisms governing reading frame choice of immunoglobulin diversity genes. Immunol. Today 18:37-43.
59. Harmsen MM, Ruuls RC, Nijman IJ, Niewold TA, Frenken LG, de Geus B. 2000. Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol. Immunol. 37:579-590.
60. Zemlin M, Klinger M, Link J, Zemlin C, Bauer K, Engler JA, Schroeder HW, Jr, Kirkham PM. 2003. Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. J. Mol. Biol. 334:733-749.
61. Wu L, Oficjalska K, Lambert M, Fennell BJ, Darmanin-Sheehan A, Ni Shuilleabhain D, Autin B, Cummins E, Tchistiakova L, Bloom L, Paulsen J, Gill D, Cunningham O, Finlay WJ. 2012. Fundamental characteristics of the immunoglobulin VH repertoire of chickens in comparison with those of humans, mice, and camelids. J. Immunol. 188:322-333.
62. Chen Y, Vaine M, Wallace A, Han D, Wan S, Seaman M, Montefiori D, Wang S, Lu S. 2013. A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design. J. Virol. 87:10232-10243.